NeuroPace (NPCE)
NeuroPace on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus.
886K
Short interest
settlement 2026-10-15
8.3
Days to cover
+2.1 days vs prior
39.4%
Short share of volume
2026-11-02
531
Fails to deliver
settlement 2026-09-18
Tue 10 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in NPCE is 886,230 shares, down 69,991 shares over the last month. Over the last 48 readings it ranged from 219,406 shares (31 January 2025) to 1,115,489 shares (30 September 2025). At the reported average volume of 107K shares a day that is 8.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/npce" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 886,230 | -1.9% | 107,138 | 8.27 |
| 2026-09-30 | 903,626 | -5.5% | 146,303 | 6.18 |
| 2026-09-15 | 956,221 | +4.9% | 109,736 | 8.71 |
| 2026-08-31 | 911,415 | +7.8% | 145,058 | 6.28 |
| 2026-08-14 | 845,369 | +2.8% | 253,466 | 3.34 |
| 2026-07-31 | 822,126 | -6.0% | 208,764 | 3.94 |
| 2026-07-15 | 874,337 | -2.7% | 153,268 | 5.70 |
| 2026-06-30 | 898,587 | +46.6% | 228,821 | 3.93 |
| 2026-06-15 | 612,829 | +5.1% | 137,787 | 4.45 |
| 2026-05-29 | 582,943 | -5.0% | 148,704 | 3.92 |
| 2026-05-15 | 613,817 | -20.7% | 266,324 | 2.30 |
| 2026-04-30 | 773,845 | -15.6% | 164,458 | 4.71 |
| 2026-04-15 | 916,811 | -3.4% | 138,069 | 6.64 |
| 2026-03-31 | 948,788 | +1.1% | 225,753 | 4.20 |
| 2026-03-13 | 938,963 | +16.6% | 295,557 | 3.18 |
| 2026-02-27 | 805,229 | -7.4% | 137,499 | 5.86 |
| 2026-02-13 | 869,265 | +9.8% | 162,224 | 5.36 |
| 2026-01-30 | 791,612 | -11.4% | 139,377 | 5.68 |
| 2026-01-15 | 893,691 | +3.2% | 349,819 | 2.55 |
| 2025-12-31 | 866,207 | -7.5% | 185,485 | 4.67 |
| 2025-12-15 | 936,577 | -1.4% | 222,935 | 4.20 |
| 2025-11-28 | 950,333 | -4.3% | 276,695 | 3.43 |
| 2025-11-14 | 992,733 | +3.6% | 329,697 | 3.01 |
| 2025-10-31 | 957,773 | -11.6% | 122,907 | 7.79 |
| 2025-10-15 | 1,083,656 | -2.9% | 121,020 | 8.95 |
| 2025-09-30 | 1,115,489 | +18.1% | 181,908 | 6.13 |
| 2025-09-15 | 944,906 | -6.1% | 180,227 | 5.24 |
| 2025-08-29 | 1,006,363 | +0.9% | 201,142 | 5.00 |
| 2025-08-15 | 997,496 | -10.1% | 208,172 | 4.79 |
| 2025-07-31 | 1,108,942 | +23.7% | 197,982 | 5.60 |
| 2025-07-15 | 896,542 | +14.6% | 228,311 | 3.93 |
| 2025-06-30 | 782,253 | +119.3% | 533,335 | 1.47 |
| 2025-06-13 | 356,665 | +0.3% | 303,232 | 1.18 |
| 2025-05-30 | 355,768 | -11.2% | 657,222 | 1.00 |
| 2025-05-15 | 400,485 | +1.7% | 278,188 | 1.44 |
| 2025-04-30 | 393,663 | +13.3% | 125,868 | 3.13 |
| 2025-04-15 | 347,479 | -22.7% | 193,319 | 1.80 |
| 2025-03-31 | 449,552 | +45.8% | 217,189 | 2.07 |
| 2025-03-14 | 308,344 | +25.6% | 257,650 | 1.20 |
| 2025-02-28 | 245,600 | +7.7% | 275,702 | 1.00 |
| 2025-02-14 | 227,953 | +3.9% | 325,225 | 1.00 |
| 2025-01-31 | 219,406 | -17.8% | 216,043 | 1.02 |
| 2025-01-15 | 267,000 | +1.4% | 101,389 | 2.63 |
| 2024-12-31 | 263,288 | +4.8% | 71,136 | 3.70 |
| 2024-12-13 | 251,350 | +0.8% | 67,135 | 3.74 |
| 2024-11-29 | 249,421 | -14.1% | 59,588 | 4.19 |
| 2024-11-15 | 290,399 | -33.7% | 120,982 | 2.40 |
| 2024-10-31 | 437,934 | -14.0% | 99,019 | 4.42 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of NPCE volume is 39.4%, down 20.8 points over the last five sessions. Over the last 30 readings it ranged from 16.3% (30 September 2026) to 64.2% (23 October 2026). The latest reading is in line with the 30-session average of 41.2%, on 30K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 12K | 30K | 39.4% | 0 |
| 2026-10-30 | 9K | 26K | 34.5% | 76 |
| 2026-10-29 | 14K | 22K | 60.8% | 0 |
| 2026-10-28 | 15K | 39K | 38.6% | 0 |
| 2026-10-27 | 6K | 17K | 35.2% | 0 |
| 2026-10-26 | 16K | 26K | 60.2% | 0 |
| 2026-10-23 | 8K | 12K | 64.2% | 0 |
| 2026-10-22 | 11K | 36K | 31.9% | 0 |
| 2026-10-21 | 11K | 18K | 63.0% | 4,582 |
| 2026-10-20 | 21K | 37K | 56.7% | 0 |
| 2026-10-19 | 16K | 32K | 49.0% | 0 |
| 2026-10-16 | 8K | 35K | 21.9% | 0 |
| 2026-10-15 | 12K | 22K | 55.6% | 0 |
| 2026-10-14 | 9K | 28K | 31.9% | 0 |
| 2026-10-13 | 8K | 14K | 56.4% | 0 |
| 2026-10-12 | 5K | 17K | 28.5% | 0 |
| 2026-10-09 | 14K | 25K | 55.1% | 0 |
| 2026-10-08 | 10K | 20K | 47.1% | 0 |
| 2026-10-07 | 15K | 43K | 36.1% | 0 |
| 2026-10-06 | 15K | 29K | 50.5% | 0 |
| 2026-10-05 | 19K | 46K | 42.1% | 0 |
| 2026-10-02 | 8K | 34K | 24.5% | 0 |
| 2026-10-01 | 21K | 58K | 37.0% | 0 |
| 2026-09-30 | 8K | 49K | 16.3% | 0 |
| 2026-09-29 | 8K | 26K | 29.2% | 0 |
| 2026-09-28 | 13K | 32K | 40.6% | 0 |
| 2026-09-25 | 13K | 76K | 17.1% | 0 |
| 2026-09-24 | 31K | 94K | 33.1% | 0 |
| 2026-09-23 | 23K | 55K | 41.8% | 0 |
| 2026-09-22 | 14K | 39K | 36.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 18 September 2026, the fails-to-deliver balance in NPCE is 531 shares, up 529 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (2 September 2026) to 14,000 shares (24 November 2025). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-18 | 531 | $14.15 | $8K |
| 2026-09-02 | 2 | $14.74 | $29 |
| 2026-08-20 | 28 | $14.64 | $410 |
| 2026-08-11 | 97 | $14.88 | $1K |
| 2026-08-06 | 29 | $13.70 | $397 |
| 2026-07-13 | 857 | $17.11 | $15K |
| 2026-06-23 | 4,072 | $15.37 | $63K |
| 2026-06-18 | 108 | $15.16 | $2K |
| 2026-05-14 | 299 | $15.81 | $5K |
| 2026-05-01 | 6 | $16.86 | $101 |
| 2026-04-30 | 62 | $16.54 | $1K |
| 2026-04-15 | 6 | $15.35 | $92 |
| 2026-03-23 | 320 | $13.00 | $4K |
| 2026-02-27 | 4,310 | $15.02 | $65K |
| 2026-02-17 | 469 | $15.05 | $7K |
| 2026-02-10 | 170 | $15.26 | $3K |
| 2026-02-06 | 11 | $15.49 | $170 |
| 2026-02-05 | 11 | $16.09 | $177 |
| 2026-01-21 | 256 | $16.52 | $4K |
| 2025-12-24 | 56 | $16.35 | $916 |
| 2025-12-22 | 350 | $16.59 | $6K |
| 2025-12-17 | 5,888 | $15.88 | $94K |
| 2025-12-12 | 2,042 | $16.48 | $34K |
| 2025-12-02 | 1,730 | $15.65 | $27K |
| 2025-11-24 | 14,000 | $14.35 | $201K |
| 2025-10-27 | 2,275 | $10.48 | $24K |
| 2025-10-21 | 8 | $10.74 | $86 |
| 2025-10-15 | 126 | $10.82 | $1K |
| 2025-09-15 | 219 | $9.86 | $2K |
| 2025-09-09 | 152 | $9.71 | $1K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for NPCE in the last 90 days. The most recent filings are listed below. Latest filing: Morrell Martha (CHIEF MEDICAL OFFICER) on 2026-09-24.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 335 | $13.97 | $5K | 51K |
| 2026-09-20 | Williams Patrick F. | Chief Financial Officer | Tax withholding | 1K | $14.28 | $17K | 68K |
| 2026-09-03 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1K | $14.75 | $19K | 138K |
| 2026-08-27 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 358 | $14.13 | $5K | 52K |
| 2026-08-27 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1K | $14.13 | $16K | 139K |
| 2026-06-24 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 335 | $16.22 | $5K | 52K |
| 2026-06-19 | Kumar Rakhi | Director | Grant | 989 | $15.63 | $15K | 23K |
| 2026-06-19 | Fischer Frank M | Director | Grant | 1K | $15.63 | $23K | 600K |
| 2026-06-19 | Geiger Uri | Director | Grant | 789 | $15.63 | $12K | 19K |
| 2026-06-05 | Ryan Renee | Director | Grant | 3K | $0.00 | $0 | 3K |
| 2026-06-05 | Kumar Rakhi | Director | Grant | 3K | $0.00 | $0 | 22K |
| 2026-06-05 | Huennekens R Scott | Director | Grant | 3K | $0.00 | $0 | 3K |
| 2026-06-05 | Geiger Uri | Director | Grant | 3K | $0.00 | $0 | 18K |
| 2026-06-05 | Fischer Frank M | Director | Grant | 3K | $0.00 | $0 | 598K |
| 2026-06-05 | Andrade Lisa | Director | Grant | 3K | $0.00 | $0 | 3K |
| 2026-06-03 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1K | $15.88 | $20K | 140K |
| 2026-05-27 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 358 | $17.06 | $6K | 52K |
| 2026-05-27 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1K | $17.06 | $19K | 142K |
| 2026-05-15 | Williams Patrick F. | Chief Financial Officer | Grant | 17K | $0.00 | $0 | 69K |
| 2026-05-15 | Morrell Martha | CHIEF MEDICAL OFFICER | Grant | 5K | $0.00 | $0 | 53K |
| 2026-05-15 | Becker Joel | CHIEF EXECUTIVE OFFICER | Grant | 46K | $0.00 | $0 | 143K |
| 2026-03-24 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $13.27 | $18K | 47K |
| 2026-03-20 | Kumar Rakhi | Director | Grant | 1K | $13.00 | $15K | 19K |
| 2026-03-20 | Fischer Frank M | Director | Grant | 2K | $13.00 | $24K | 595K |
| 2026-03-20 | LACOB JOSEPH | Director | Grant | 865 | $13.00 | $11K | 15K |
| 2026-03-20 | Geiger Uri | Director | Grant | 913 | $13.00 | $12K | 15K |
| 2026-03-03 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $13.83 | $19K | 49K |
| 2026-03-03 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 5K | $13.83 | $69K | 97K |
| 2026-02-27 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 358 | $14.58 | $5K | 75K |
| 2026-02-27 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1K | $14.58 | $16K | 102K |
| 2026-02-20 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 3K | $14.34 | $49K | 75K |
| 2025-12-19 | LACOB JOSEPH | Director | Grant | 678 | $16.59 | $11K | 14K |
| 2025-12-19 | Kumar Rakhi | Director | Grant | 904 | $16.59 | $15K | 18K |
| 2025-12-19 | Geiger Uri | Director | Grant | 715 | $16.59 | $12K | 14K |
| 2025-12-19 | Fischer Frank M | Director | Grant | 1K | $16.59 | $24K | 593K |
| 2025-12-15 | Morrell Martha | CHIEF MEDICAL OFFICER | Sell | 25K | $15.97 | $399K | 50K |
| 2025-12-03 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $16.66 | $22K | 79K |
| 2025-11-27 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 357 | $16.50 | $6K | 80K |
| 2025-11-27 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1K | $16.50 | $19K | 103K |
| 2025-11-20 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 3K | $13.50 | $41K | 80K |
| 2025-09-19 | LACOB JOSEPH | Director | Grant | 1K | $9.94 | $11K | 13K |
| 2025-09-19 | Kumar Rakhi | Director | Grant | 2K | $9.94 | $15K | 17K |
| 2025-09-19 | Geiger Uri | Director | Grant | 1K | $9.94 | $12K | 13K |
| 2025-09-19 | Fischer Frank M | Director | Grant | 2K | $9.94 | $24K | 592K |
| 2025-09-03 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $9.36 | $13K | 83K |
| 2025-08-27 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 357 | $8.88 | $3K | 85K |
| 2025-08-27 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1K | $8.88 | $10K | 104K |
| 2025-08-20 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 3K | $8.66 | $26K | 85K |
| 2025-06-21 | LACOB JOSEPH | Director | Grant | 1K | $10.41 | $11K | 12K |
| 2025-06-21 | Kumar Rakhi | Director | Grant | 1K | $10.41 | $15K | 16K |
| 2025-06-21 | Geiger Uri | Director | Grant | 1K | $10.41 | $12K | 12K |
| 2025-06-21 | Fischer Frank M | Director | Grant | 2K | $10.41 | $24K | 590K |
| 2025-06-20 | Williams Patrick F. | Chief Financial Officer | Grant | 52K | $0.00 | $0 | 52K |
| 2025-06-03 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $13.54 | $18K | 86K |
| 2025-06-03 | Kuhn Rebecca | CHIEF FINANCIAL OFFICER | Tax withholding | 1K | $13.54 | $18K | 132K |
| 2025-05-27 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 357 | $12.66 | $5K | 87K |
| 2025-05-27 | Kuhn Rebecca | CHIEF FINANCIAL OFFICER | Tax withholding | 357 | $12.66 | $5K | 133K |
| 2025-05-27 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1K | $12.66 | $14K | 105K |
| 2025-05-20 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 3K | $17.99 | $55K | 88K |
| 2025-05-20 | Kuhn Rebecca | CHIEF FINANCIAL OFFICER | Tax withholding | 3K | $17.99 | $55K | 133K |
| 2025-05-14 | ORBIMED ADVISORS LLC | TenPercentOwner | Sell | 134K | $15.83 | $2.1M | 3.3M |
| 2025-05-14 | ORBIMED ADVISORS LLC | TenPercentOwner | Sell | 34K | $15.94 | $542K | 3.2M |
| 2025-04-22 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 237 | $10.94 | $3K | 91K |
| 2025-04-22 | Kuhn Rebecca | CHIEF FINANCIAL OFFICER | Tax withholding | 237 | $10.94 | $3K | 136K |
| 2025-03-24 | Morrell Martha | CHIEF MEDICAL OFFICER | Grant | 12K | $0.00 | $0 | 91K |
| 2025-03-21 | LACOB JOSEPH | Director | Grant | 935 | $12.02 | $11K | 11K |
| 2025-03-21 | Kumar Rakhi | Director | Grant | 1K | $12.02 | $15K | 14K |
| 2025-03-21 | Geiger Uri | Director | Grant | 987 | $12.02 | $12K | 11K |
| 2025-03-21 | Fischer Frank M | Director | Grant | 2K | $12.02 | $24K | 587K |
| 2025-03-10 | Becker Joel | CHIEF EXECUTIVE OFFICER | Grant | 59K | $0.00 | $0 | 106K |
| 2025-03-10 | Kuhn Rebecca | CHIEF FINANCIAL OFFICER | Grant | 12K | $0.00 | $0 | 137K |
| 2025-03-03 | Kuhn Rebecca | CHIEF FINANCIAL OFFICER | Tax withholding | 1K | $11.81 | $16K | 125K |
| 2025-03-03 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $11.81 | $16K | 79K |
| 2025-02-27 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $12.56 | $18K | 81K |
| 2025-02-27 | Kuhn Rebecca | CHIEF FINANCIAL OFFICER | Tax withholding | 1K | $12.56 | $18K | 126K |
| 2025-02-27 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 5K | $12.56 | $57K | 48K |
| 2025-02-21 | Morrell Martha | CHIEF MEDICAL OFFICER | Sell | 78K | $13.72 | $1.1M | 82K |
| 2025-02-20 | KCK LTD. | TenPercentOwner | Sell | 5.3M | $9.40 | $49.5M | 0 |
| 2025-02-20 | Kuhn Rebecca | Chief Financial Officer | Tax withholding | 3K | $14.23 | $48K | 128K |
| 2025-02-20 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 3K | $14.23 | $48K | 44K |
| 2025-01-30 | Morrell Martha | CHIEF MEDICAL OFFICER | Sell | 200 | $15.00 | $3K | 87K |
| 2025-01-29 | Morrell Martha | CHIEF MEDICAL OFFICER | Sell | 100 | $15.00 | $2K | 87K |
| 2025-01-24 | Morrell Martha | CHIEF MEDICAL OFFICER | Sell | 3K | $15.01 | $48K | 87K |
| 2025-01-22 | Kuhn Rebecca | Chief Financial Officer | Tax withholding | 265 | $14.04 | $4K | 118K |
| 2025-01-22 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 265 | $14.04 | $4K | 47K |
| 2024-12-21 | LACOB JOSEPH | Director | Grant | 975 | $11.53 | $11K | 10K |
| 2024-12-21 | Kumar Rakhi | Director | Grant | 1K | $11.53 | $15K | 13K |
| 2024-12-21 | Geiger Uri | Director | Grant | 1K | $11.53 | $12K | 10K |
| 2024-12-21 | Fischer Frank M | Director | Grant | 2K | $11.53 | $24K | 585K |
| 2024-12-03 | Kuhn Rebecca | Chief Financial Officer | Tax withholding | 1K | $11.93 | $16K | 118K |
| 2024-12-03 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $11.93 | $17K | 47K |
| 2024-11-20 | Kuhn Rebecca | Chief Financial Officer | Tax withholding | 3K | $9.19 | $28K | 120K |
| 2024-11-20 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 3K | $9.19 | $28K | 49K |
| 2024-10-25 | KCK LTD. | TenPercentOwner | Sell | 224K | $5.45 | $1.2M | 5.3M |
| 2024-10-23 | KCK LTD. | TenPercentOwner | Sell | 147 | $6.02 | $885 | 5.5M |
| 2024-10-22 | Kuhn Rebecca | Chief Financial Officer | Tax withholding | 237 | $6.00 | $1K | 123K |
| 2024-10-22 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 237 | $6.00 | $1K | 52K |
| 2024-10-22 | KCK LTD. | TenPercentOwner | Sell | 4K | $6.09 | $25K | 5.5M |
| 2024-10-21 | KCK LTD. | TenPercentOwner | Sell | 4K | $6.10 | $23K | 5.5M |
| 2024-10-18 | KCK LTD. | TenPercentOwner | Sell | 5K | $6.29 | $31K | 5.5M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for NPCE worth $405K at the prices reported; 0 in the last 90 days worth $0. Latest: MARTHA J MORRELL filed on 2025-12-15 to sell 25,000 shares ($405K) from 2025-12-15.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2025-12-15 | MARTHA J MORRELLOfficer | 25K | $405K | 0.075% | 2025-12-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON8 holders report 5% or more of NPCE in their latest filing, all on Schedule 13G (passive). The largest reported stake is Mathew P. Arens at 12.3% of the class (4,203,931 shares), filed 2026-09-04 for an event on 2026-08-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-04 | 13G/Ano. 1 | Mathew P. Arensindividual | 4.2M | 12.3% | 2026-08-31 |
| 2026-09-04 | 13G/Ano. 1 | First Light Asset Management, LLCinvestment adviser | 4.0M | 11.8% | 2026-08-31 |
| 2026-08-14 | 13G/Ano. 8 | OrbiMed Advisors LLCinvestment adviser | 1.5M | 4.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 8 | OrbiMed Capital GP VI LLCother entity | 1.5M | 4.4% | 2026-06-30 |
| 2025-11-07 | 13G/Ano. 6 | Guy Levyindividual | 3.0M | 8.9% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 6 | Soleus Capital Management, L.P.partnership | 2.9M | 8.9% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 6 | Soleus GP, LLCother entity | 2.9M | 8.9% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 6 | Soleus Capital Master Fund, L.P.non-US institution | 2.6M | 7.9% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 6 | Soleus Capital, LLCother entity | 2.6M | 7.9% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 6 | Soleus Capital Group, LLCother entity | 2.6M | 7.9% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 6 | Soleus Private Equity Fund I, L.P.partnership | 310K | 0.9% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 6 | Soleus Private Equity GP I, LLCother entity | 310K | 0.9% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 6 | Soleus PE GP I, LLCother entity | 310K | 0.9% | 2025-09-30 |
13F holders
Tracked managers holding NPCE at their latest 13F. JSON6 of the 30 tracked managers held NPCE at their latest 13F, $7.9M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $2.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 161K | $2.6M | 0.00% | +117K |
| Citadel Advisors | 2026-06-30 | 129K | $2.0M | 0.00% | +42K |
| Renaissance Technologies | 2026-06-30 | 112K | $1.8M | 0.00% | -63K |
| AQR Capital Management | 2026-06-30 | 36K | $571K | 0.00% | +8K |
| Millennium Management | 2026-06-30 | 31K | $487K | 0.00% | -10K |
| Two Sigma Investments | 2026-06-30 | 30K | $480K | 0.00% | -44K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) NeuroPace reported revenue of $22.8M, up 17.1% from the same quarter a year earlier, and net loss of $6.2M (-0.18 diluted EPS). In FY 2025 it generated -$11.0M of operating cash flow and spent $49.5M on buybacks. As of 2026-06-30, cash was $12.5M against $59.0M of debt.
- Cash
- $12.5M
- Debt
- $59.0M
- Equity
- $11.9M
- Total assets
- $97.0M
- Shares outstanding
- 34,324,274
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $22.8M | -$6.2M | -27.2% | -0.18 |
| Q1 FY 2026 | 2026-03-31 | $22.1M | -$6.7M | -30.3% | -0.20 |
| Q4 FY 2025derived | 2025-12-31 | $30.6M | -$2.7M | -8.9% | n/a |
| Q3 FY 2025 | 2025-09-30 | $27.4M | -$3.5M | -12.8% | -0.11 |
| Q2 FY 2025 | 2025-06-30 | $19.5M | -$8.7M | -44.4% | -0.26 |
| Q1 FY 2025 | 2025-03-31 | $22.5M | -$6.6M | -29.3% | -0.21 |
| Q4 FY 2024derived | 2024-12-31 | $21.5M | -$5.3M | -24.5% | n/a |
| Q3 FY 2024 | 2024-09-30 | $21.1M | -$5.5M | -25.9% | -0.19 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $100.0M | -$21.5M | -$11.0M | $332K | $49.5M | n/a |
| FY 2024 | 2024-12-31 | $79.9M | -$27.1M | -$17.9M | $306K | $0 | n/a |
| FY 2023 | 2023-12-31 | $65.4M | -$33.0M | -$19.7M | $173K | n/a | n/a |
| FY 2022 | 2022-12-31 | $45.5M | -$47.1M | -$36.9M | $603K | n/a | n/a |
| FY 2021 | 2021-12-31 | $45.2M | -$36.1M | -$24.6M | $384K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-07 from the cover page.
What this page is
NeuroPace in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows NeuroPace (NPCE), SEC CIK 1528287, listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-18.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2025-12-15.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-04.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-24.JSON and CSV
- Company record
- EDGAR filing index for CIK 1528287Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
Other company pages
Datasets
Frequently Asked Questions
How much of NPCE is sold short?
What is NPCE's daily short volume?
Does NPCE have fails to deliver?
Are NPCE insiders buying or selling?
Have NPCE insiders filed to sell?
Who owns 5% or more of NPCE?
What did NPCE report last quarter?
Which tracked 13F managers own NPCE?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.